Cardiac arrhythmias 2005: proceedings of the 9th international workshop on cardiac arrhythmias - Venice, October 2-5 2005

Front Matter....Pages 1-1
Right and Left Atrial Flutter: How To Differentiate Them on the Basis of Surface Electrocardiogram?....Pages 3-12
Atypical Atrial Flutter: How to Diagnose, Locate, and Ablate It....Pages 13-19
Catheter Ablation of Typical Atrial Flutter. What Are the Long-Term Results and Predictors of Recurrences?....Pages 21-31
Atrial Fibrillation After Ablation of Atrial Flutter: Who Is at Risk?....Pages 33-38
Electroanatomic Mapping to Support Ablation of Complex Supraventricular Arrhythmias: Does It Matter?....Pages 39-54
Front Matter....Pages 55-55
Idiopathic Atrial Fibrillation: Which Electrophysiological Substrate?....Pages 57-60
Inflammation and Infection: Underestimated Causes of Atrial Fibrillation?....Pages 61-66
Atrial Remodelling: What Have We Learned in the Last Decade?....Pages 67-73
Atrial Fibrillation and Heart Failure: Does One Epidemic Feed the Other?....Pages 75-82
Atrial Fibrillation: What Is the Impact of the Different Therapies on Quality of Life?....Pages 83-88
‘Pill-In-The-Pocket’ Approach for Outpatient Treatment of Recent Onset Atrial Fibrillation: The Obvious Solution?....Pages 89-94
Pharmacological Cardioversion of Atrial Fibrillation: Which Drugs Are Preferred, Class IC or Class III?....Pages 95-100
Early Recurrences of Atrial Fibrillation: How To Predict Them?....Pages 101-107
Dronedarone for Prevention of Atrial Fibrillation: An Unfulfilled Promise?....Pages 109-115
Prognosis and Management of Atrial Fibrillation in Patients Without Structural Heart Disease....Pages 117-120
Primary Prevention of Atrial Fibrillation in Hypertensive Patients: What Is New from the LIFE Trial?....Pages 121-126
Prognosis and Management of Atrial Fibrillation in Different Clinical Settings: Acute Myocardial Infarction....Pages 127-130
Post-CABG Atrial Fibrillation: What Are the Incidence, Predictors, Treatment, and Long-Term Outcome?....Pages 131-136
Post-PCI Atrial Fibrillation: Possible Clinical and Prognostic Significance....Pages 137-143
Perioperative Interruption of Warfarin: How Effective and Safe Is Bridging Therapy with Low-Molecular-Weight Heparin?....Pages 145-150
Front Matter....Pages 55-55
How Safe Is Anticoagulant Therapy in Older Patients and What Should Be the INR Target?....Pages 151-157
Oral Antithrombin Agents: Will They Replace Warfarin?....Pages 159-167
Guidelines for Anticoagulation of Atrial Fibrillation: Is It Time for an Update?....Pages 169-176
Front Matter....Pages 177-177
Anatomy of the Left Atrium and Pulmonary Veins: What Have We Learned in Recent Years?....Pages 179-187
Imaging in Arrhythmic Syndromes: What Is the Role of Cardiac Radiology?....Pages 189-196
Value of Transoesophageal Echocardiography for the Ablation of Atrial Fibrillation....Pages 197-204
Value of the LocaLisa Non-fluoroscopic Mapping System in the Ablation of Atrial Fibrillation....Pages 205-211
Linear Atrial Lesions Should Always Be Performed in Addition to Circumferential Pulmonary Vein Isolation....Pages 213-215
Systematic Electrical Disconnection of Superior Vena Cava in Addition to Pulmonary Vein Ablation: Is It Worthwhile?....Pages 217-222
What Is the Outcome of Atrial Fibrillation Ablation in Patients with Left Ventricular Dysfunction?....Pages 223-230
Complications of Atrial Fibrillation Ablation: How to Prevent and Manage Cerebrovascular Accidents....Pages 231-239
Pulmonary Vein Stenosis After Catheter Ablation of Atrial Fibrillation....Pages 241-250
Atrial Fibrillation Should Be Considered a First-Line Therapy — Or Not?....Pages 251-256
Long-Term Use of the Atrial and Dual Defibrillator: What Have We Learned?....Pages 257-265
Hybrid Therapy as an Alternative in Refractory Atrial Fibrillation: When, Why, and How?....Pages 267-278
Atrial Fibrillation and Transcatheter Ablation: ‘Ablate And Pace’ or Pulmonary Veins Disconnection?....Pages 279-288
Front Matter....Pages 289-289
Fever and Other Precipitants of Ventricular Arrhythmias in Brugada Syndrome: Do We Know How They Act?....Pages 291-302
Drug Challenge in Brugada Syndrome: How Valuable Is It?....Pages 303-315
Electrophysiologic Study in Brugada Syndrome: More Questions Than Answers?....Pages 317-321
Short QT Syndrome: How Frequent Is It and What Are Its Peculiar Features?....Pages 323-326
Front Matter....Pages 289-289
ICD Therapy for Short QT Syndrome: The Risk of Inappropriate Shocks and How to Avoid Them....Pages 327-332
Quinidine to Treat Short QT Syndrome: A Real Alternative to ICD?....Pages 333-335
ICD for the Long QT Syndrome: Which Indications, Complications, and Results?....Pages 337-344
How To Differentiate Right Ventricular Outflow Tract Tachycardia from Arrhythmogenic Right Ventricular Cardiomyopathy?....Pages 345-349
How To Diagnose and Approach Epicardial Ventricular Tachycardia....Pages 351-361
Front Matter....Pages 363-363
Predicting the Sudden Death in the Athlete....Pages 365-371
New Markers of Sudden Cardiac Death: Genetic Variables....Pages 373-383
Sudden Arrhythmic Death: Which Genetic Determinants?....Pages 385-392
Brain Natriuretic Peptide as a Predictor of Sudden Cardiac Death....Pages 393-398
Non-Esterified Fatty Acids as Markers of Sudden Death....Pages 399-407
Value of Angiotensin-Converting Enzyme Inhibitors to Prevent Sudden Death....Pages 409-413
Value of Non-antiarrythmic Drugs in Preventing Sudden Cardiac Death: Aldosterone Antagonists....Pages 415-423
After DEFINITE, SCD-HeFT, COMPANION: Do We Need to Implant an ICD in All Patients With Heart Failure?....Pages 425-434
Health Care Systems: How to Resolve the Dilemma Between Clinical Needs and Limited Resources?....Pages 435-445
Cost-Effectiveness and Aspects of Health Economics in Primary Prevention: What Is the Case of Dilated Cardiomyopathy?....Pages 447-453
Public Access Defibrillation: How Widespread Is It and What Are the Short-Term and Long-Term Results?....Pages 455-461
In-Hospital Cardiac Arrest: How to Improve Survival?....Pages 463-471
Front Matter....Pages 473-473
Usefulness of Conventional Transthoracic Echocardiography in Selecting Heart Failure Patients Likely to Benefit from Cardiac Resynchronisation Therapy....Pages 475-479
Three-Dimensional Echocardiography: Which Role for CRT Patients?....Pages 481-483
Upgrading From Right Ventricular to Biventricular Pacing: When, Why, and How?....Pages 485-490
Front Matter....Pages 473-473
Cardiac Resynchronisation Therapy: How to Identify Patients Who Will not Respond to Therapy....Pages 491-501
Controversial and Emerging Indication for CRT: Atrial Fibrillation....Pages 503-510
Cardiac Resynchronisation Therapy in Patients with NYHA Class I–II....Pages 511-517
Cardiac Resynchronisation Therapy: Is It Antiarrhythmic or Proarrhythmic?....Pages 519-526
Impact of CRT on Mortality: What Are the Preliminary Results from the CARE-HF Trial?....Pages 527-530
Loss of Resynchronisation by Biventricular Pacemakers: Mechanisms, Diagnosis and Therapy....Pages 531-545
Front Matter....Pages 547-547
Right Ventricular Pacing: Is It Really That Bad?....Pages 549-555
The Importance of Minimising Right Ventricular Pacing in Patients with Sick Sinus Syndrome: Why and How?....Pages 557-568
Drug-Induced, Drug-Provoked and Drug-Associated Bradycardia....Pages 569-574
The Sleep Apnoea Syndrome: CPAP or Cardiac Pacing?....Pages 575-579
Rate-Responsive Pacing Controlled by the TVI Sensor in the Treatment of Sick Sinus Syndrome....Pages 581-590
Preliminary Test of a New Haemodynamic Pacemaker: Evaluation of Sensor Safety....Pages 591-598
From Analog to Digital Technology: What Are the Clinical Benefits?....Pages 599-605
What Are the Benefits of Morphological Signal Analysis Using Digital Technology?....Pages 607-608
How Can New Technologies Help Make Follow-Up Easier?....Pages 609-616
Interference of Cellular Phones and Metal Detectors With Pacemakers and ICDs: Still a Problem?....Pages 617-625
Can Patients With Implanted Pacemakers/ICD Undergo Magnetic Resonance Imaging?....Pages 627-630
Front Matter....Pages 631-631
Syncope in Children and Adolescents: What Are the Peculiar Features?....Pages 633-641
Syncope in Patients with Autonomic Nervous System Disturbances: Which Diagnosis and Treatment?....Pages 643-653
Organisation of Syncope Management Units: The North American Experience....Pages 655-658
Front Matter....Pages 631-631
The Syncope Unit: How To Better Organise It? The European Experience....Pages 659-664
Water Ingestion As Prophylaxis Against Syncope: Fact or Fancy?....Pages 665-673
Counter-Pressure Manoeuvres to Abort Impeding Syncope: Are They Really Useful?....Pages 675-679
Compression Stockings to Combat Vasovagal Syncope: What Is the Rationale?....Pages 681-686
β-Blockers for Prevention of Vasovagal Syncope: Who Benefits from Treatment?....Pages 687-694
Has Psychiatric Treatment Any Role in the Management of Vasovagal Syncope?....Pages 695-700
Familial Vasovagal Syncope: Clinical Characteristics and Potential Genetic Substrates....Pages 701-708